MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
Armistice Capital, LLCSchedule 13G/A reporting beneficial ownership of 6,012,000 shares of Macrogenics, Inc. common stock, representing 9.46% of the class as of 03/31/2026. The filing explains Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive proceeds and dividends; the Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The joint filing is signed by Steven Boyd on 05/15/2026.
MacroGenics, Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 3,066,926 shares of MacroGenics common stock, representing 4.8% of the class. The reporting persons state they acquired beneficial ownership of more than 5% on 05/08/2026 and ceased to be beneficial owners of more than 5% by the date of this filing. The filing is submitted jointly and includes a Joint Filing Agreement dated 05/13/2026.
Bank of America Corp reported beneficial ownership of 3,258,574 shares of MacroGenics, Inc. common stock, equal to 5.1% of the class. The filing bases its calculation on 63,560,068 outstanding shares as of March 27, 2026.
The statement is a Schedule 13G filed on behalf of Bank of America and certain subsidiaries, listing shared voting and dispositive power over the reported shares. The filing is signed by an authorized signatory on May 14, 2026.
MacroGenics reported a first quarter 2026 net loss of $36.8 million on revenue of $20.8 million, while unveiling a major strategic shift in its operations. Revenue grew from $13.2 million a year earlier, driven by higher contract manufacturing and ZYNYZ royalty revenue, while R&D and G&A expenses both declined.
The company agreed to sell its Maryland manufacturing operations to Bora Pharmaceuticals for an expected $122.5 million upfront and expanded monetization of its ZYNYZ royalties with Sagard Healthcare Partners for $60.0 million plus up to $20.0 million more based on 2026 sales. These transactions, together with existing cash of $154.2 million as of March 31, 2026, are expected to extend MacroGenics’ cash runway through 2028 as it focuses on its antibody-drug conjugate and bispecific pipeline.
MacroGenics reported higher Q1 2026 revenue but remains loss‑making while shoring up liquidity through royalty and asset deals. Total revenue rose to $20.8 million from $13.2 million, driven mainly by contract manufacturing revenue of $14.0 million and royalty revenue of $6.2 million from ZYNYZ sales.
The net loss narrowed to $36.8 million from $41.0 million, as research and development spending fell to $35.0 million and general and administrative costs to $9.7 million. Cash and cash equivalents were $66.5 million and marketable securities $87.7 million as of March 31, 2026, after using $35.8 million in operating cash.
The company continues to monetize partnered assets. A 2025 royalty financing on ZYNYZ created a $68.7 million non‑cash royalty liability, and a May 2026 amendment added a further $60.0 million payment and revised caps. MacroGenics also agreed to sell its CDMO manufacturing operations to Bora for $122.5 million plus up to $5.0 million in milestones, and now anticipates its cash runway extends through 2028 while advancing three proprietary oncology programs and multiple partnered candidates.
MacroGenics, Inc. entered into an Asset Purchase Agreement to sell its GMP drug substance manufacturing and CDMO operations in Maryland to Bora Pharmaceuticals for an upfront cash payment of $122.5 million, subject to customary adjustments and closing conditions. The agreement also includes up to $5 million in potential post-closing cash payments tied to manufacturing milestones and professional development services in 2027 and 2028. Bora will assume the Rockville manufacturing site with total capacity of 11,000 liters, the Frederick warehouse, and is expected to hire approximately 140 MacroGenics employees. At closing, MacroGenics and Bora plan to enter a manufacturing and supply agreement, a transition services agreement, and a sublease, with the transaction expected to close in the third quarter of 2026.
MacroGenics, Inc. entered into a first amendment to its ZYNYZ royalty purchase agreement with Sagard Healthcare Partners, providing an additional $60.0 million in cash and bringing the aggregate purchase price to $130.0 million.
In exchange, Sagard’s capped royalty interest on future global net sales of ZYNYZ was revised so that all royalty rights under the Incyte license will revert to MacroGenics once Sagard has received either 1.70x the $130.0 million aggregate purchase price by September 30, 2032, or 2.0x that amount thereafter. MacroGenics is also eligible for a one-time 2026 sales-based milestone payment of up to $20.0 million, which would increase the aggregate purchase price used for the cap. The company retains other economic interests in ZYNYZ, including potential development, regulatory and commercial milestones.
MacroGenics, Inc. announced that the U.S. Food and Drug Administration has removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers. This allows the company to resume enrolling new participants under a revised protocol with added safeguards for potential blood and heart-related side effects.
The LINNET study is testing single-agent lorigerlimab, a bispecific DART® antibody targeting PD-1 and CTLA-4, in up to about 60 patients with platinum-resistant ovarian cancer or clear cell gynecologic cancers who have received prior therapies. To date, 41 participants have been treated in LINNET and over 300 across lorigerlimab’s Phase 1 and Phase 2 trials. MacroGenics expects to provide a clinical update on the lorigerlimab program around mid-2026.
MacroGenics will hold a virtual annual stockholder meeting on May 19, 2026. Investors are asked to elect three Class I directors, ratify Ernst & Young as auditor for 2026, approve 2025 executive pay on an advisory basis, and approve an amendment to the 2023 Equity Incentive Plan adding 1,250,000 shares for future equity awards. The company has 63,560,068 common shares outstanding as of March 27, 2026. Management highlights equity compensation as a key tool to attract and retain talent in a competitive biotech market and notes safeguards such as no option repricing without stockholder approval and a clawback policy for incentive pay.
MacroGenics Inc: The Vanguard Group filed Amendment No. 6 to its Schedule 13G/A, stating it beneficially owns 0 shares of MacroGenics common stock, equal to 0% of the class.
The filing explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report holdings separately; Vanguard states those entities pursue the same investment strategies previously followed.